<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03167541</url>
  </required_header>
  <id_info>
    <org_study_id>RB9-UK-1514</org_study_id>
    <nct_id>NCT03167541</nct_id>
  </id_info>
  <brief_title>Naproxen Sodium (2 x 220 mg) Fasted Comparative Bioavailability Study</brief_title>
  <official_title>A Randomised, Single-dose, 2-way Crossover, Open-label, Comparative Bioavailability Study Comparing Test Naproxen Sodium Tablets (2 x 220 mg) With Commercially Available Reference Naproxen Sodium Tablets (2 x 220 mg) in the Fasted State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reckitt Benckiser Healthcare (UK) Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Simbec Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Reckitt Benckiser Healthcare (UK) Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to investigate the rate and extent of naproxen absorption from
      the Test naproxen sodium formulation is bioequivalent to Aleve® naproxen sodium, a Reference
      product currently marketed in The Netherlands in order to support the registration of the
      Reckitt Benckiser (RB) naproxen sodium (220 mg tablets).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 12, 2016</start_date>
  <completion_date type="Actual">December 2, 2016</completion_date>
  <primary_completion_date type="Actual">December 2, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Plasma Concentration-time at Time t (AUC0-t)</measure>
    <time_frame>Pre-dose and at 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 15 mins, 1 hour 30 mins, 1 hour 45 mins, 2 hours, 2 hours 30 mins, 3, 4, 6, 9, 15 (Day 1), 24, 36 (Day 2), 48 (Day 3) and 72 (Day 4) hours post-dose</time_frame>
    <description>AUC0-t defines Area under the plasma concentration-time curve (AUC) from administration to the last quantifiable concentration at time t.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Pre-dose and at 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 15 mins, 1 hour 30 mins, 1 hour 45 mins, 2 hours, 2 hours 30 mins, 3, 4, 6, 9, 15 (Day 1), 24, 36 (Day 2), 48 (Day 3) and 72 (Day 4) hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Elimination Rate Constant (Kel)</measure>
    <time_frame>Pre-dose and at 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 15 mins, 1 hour 30 mins, 1 hour 45 mins, 2 hours, 2 hours 30 mins, 3, 4, 6, 9, 15 (Day 1), 24, 36 (Day 2), 48 (Day 3) and 72 (Day 4) hours post-dose</time_frame>
    <description>Elimination Rate Constant (Kel) was calculated as the absolute value of the log-linear regression slope of the elimination phase (logged) over time (linear) using the post Cmax concentrations [at least 3 non-below the limit of quantification (BLQ)] that maximised the adjusted R2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration Curve From Administration to Infinity (AUC0-inf)</measure>
    <time_frame>Pre-dose and at 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 15 mins, 1 hour 30 mins, 1 hour 45 mins, 2 hours, 2 hours 30 mins, 3, 4, 6, 9, 15 (Day 1), 24, 36 (Day 2), 48 (Day 3) and 72 (Day 4) hours post-dose</time_frame>
    <description>Area under the plasma concentration curve from administration to infinity (AUC0-inf) was calculated as AUC0-t + (Ct/Kel) where Ct was the last quantifiable concentration at time t</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Area (AUC%Extrap)</measure>
    <time_frame>Pre-dose and at 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 15 mins, 1 hour 30 mins, 1 hour 45 mins, 2 hours, 2 hours 30 mins, 3, 4, 6, 9, 15 (Day 1), 24, 36 (Day 2), 48 (Day 3) and 72 (Day 4) hours post-dose</time_frame>
    <description>AUC%extrap represents the percentage of the AUC0-inf obtained by extrapolation, calculated as (1 - [AUC0-last/AUC0-inf]) multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Until Cmax is First Achieved (Tmax)</measure>
    <time_frame>Pre-dose and at 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 15 mins, 1 hour 30 mins, 1 hour 45 mins, 2 hours, 2 hours 30 mins, 3, 4, 6, 9, 15 (Day 1), 24, 36 (Day 2), 48 (Day 3) and 72 (Day 4) hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration (Elimination) Half-life (T1/2)</measure>
    <time_frame>Pre-dose and at 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 15 mins, 1 hour 30 mins, 1 hour 45 mins, 2 hours, 2 hours 30 mins, 3, 4, 6, 9, 15 (Day 1), 24, 36 (Day 2), 48 (Day 3) and 72 (Day 4) hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration at Each Planned Nominal Time-point (Cn)</measure>
    <time_frame>Pre-dose and at 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 15 mins, 1 hour 30 mins, 1 hour 45 mins, 2 hours, 2 hours 30 mins, 3, 4, 6, 9, 15 (Day 1), 24, 36 (Day 2), 48 (Day 3) and 72 (Day 4) hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events (AEs)</measure>
    <time_frame>Up to follow-up day 7</time_frame>
    <description>Intensity was determined by the Investigator
Mild = AE does not limit usual activities; subject may experience slight discomfort.
Moderate = AE results in some limitation of usual activities; subject may experience significant discomfort.
Severe = AE results in an inability to carry out usual activities; subject may experience intolerable discomfort or pain.
Relationship to Investigational Medicinal Products (IMP)
Certain = AE was definitely caused by IMP. Probable = Most likely that the AE was caused by IMP. Possible = Reasonable suspicion that the AE was caused by IMP Unlikely = Slight, but remote, chance that the AE was caused by IMP but the balance of judgment is that it was most likely not due to the IMP.
Unrelated = No possibility that the AE was caused by IMP Un-assessable/Unclassified = Insufficient information to be able to make an assessment.
Conditional/Unclassified = Insufficient information to make an assessment at present.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Order: Test, Reference</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Order: Reference, Test</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test</intervention_name>
    <description>RB naproxen sodium tablets (2x220mg)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference</intervention_name>
    <description>Aleve naproxen sodium tablets (2x220mg)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects who have given written informed consent.

          2. Age: ≥ 18 years ≤ 50 years.

          3. Body Mass Index (BMI) of ≥ 20 and ≤ 30 kg/m2.

          4. Healthy as determined by past medical history, physical examination, vital signs,
             electrocardiogram (ECG), and laboratory tests at screening.

          5. Female subject of child bearing potential with a negative pregnancy test at the
             screening visit and willing to use an effective method of contraception unless of
             non-childbearing potential or where abstaining from sexual intercourse in line with
             the preferred and usual lifestyle of the subject from first dose until 3 months after
             the final dose of study medication.

          6. Female subject of non-child bearing potential with negative pregnancy test at the
             screening visit.

          7. Male subject willing to use an effective method of contraception unless anatomically
             sterile or where abstaining from sexual intercourse in line with the preferred and
             usual lifestyle of the subject from first dose until 3 months after the final dose of
             study medication.

        Exclusion Criteria:

          1. Pregnant or lactating females.

          2. Intention to become pregnant during the course of the study

          3. Lack of safe contraception.

          4. A history and/or presence of significant disease of any body system, including
             psychiatric disorders.

          5. Any condition that may currently interfere with the absorption, distribution,
             metabolism or excretion of drugs.

          6. A history of allergy or intolerance related to treatment with naproxen or other
             NSAIDs, or the excipients of the formulations.

          7. A history of or active peptic or duodenal ulcers or gastro-intestinal bleed or upper
             gastro-intestinal bleed, or other significant gastro-intestinal disorders.

          8. A history of frequent dyspepsia, e.g. heartburn or indigestion.

          9. A history of migraine.

         10. Current smokers and ex-smokers who have smoked or used nicotine replacement products
             during the previous 6 months prior to first dosing.

         11. A history of substance abuse (including alcohol).

         12. High consumption of stimulating drinks (coffee, tea, cola, energy drinks etc; total
             caffeine intake per day above 300 mg [1 cup of coffee equates to approximately 50 mg
             caffeine]).

         13. Those with positive screen/test for drugs of abuse and alcohol.

         14. Ingestion of a prescribed drug at any time in the 14 days before the first dose of
             study medication (excluding hormonal contraceptives and hormone replacement therapy),
             or consumption of enzyme inhibitors or inducers (drug, food or herb) 30 days prior to
             the first dose of study medication (such as barbiturates, carbamazepine, erythromycin,
             phenytoin, etc.).

         15. Ingestion of an over-the-counter (OTC) preparation within 7 days before the first dose
             of study medication, including herbal medications, vitamin/fish oil supplements,
             naproxen and other NSAIDs.

         16. Those who have consumed grapefruit or grapefruit juice, pummelo or Seville oranges in
             the 7 days prior to randomisation.

         17. Strenuous physical exercise from 48 hours prior to randomisation to the post study
             Follow-Up Visit.

         18. Donation of blood in quantity &gt; 400 ml or other blood products e.g. to the blood
             transfusion service or significant loss of blood in the 12 weeks prior to screening.

         19. Known human immunodeficiency virus (HIV) positive status, or a positive viral serology
             screen.

         20. Topical use of naproxen within 7 days before the first dose of study medication.

         21. Those previously randomised into this study.

         22. Those who are an employee at the study site.

         23. Those who are a partner or first degree relative of the Investigator.

         24. Receipt of an investigational product, or participation in another trial involving a
             marketed or investigational drug in the 12 weeks prior to screening.

         25. Those unable in the opinion of the Investigator to comply fully with the study
             requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Adams, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simbec Research</affiliation>
  </overall_official>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>May 17, 2017</study_first_submitted>
  <study_first_submitted_qc>May 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <results_first_submitted>October 4, 2017</results_first_submitted>
  <results_first_submitted_qc>February 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 28, 2019</results_first_posted>
  <last_update_submitted>February 26, 2019</last_update_submitted>
  <last_update_submitted_qc>February 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a single-centre study conducted in United Kingdom.</recruitment_details>
      <pre_assignment_details>Total 32 subjects were screened. Of these, 6 subjects were screen failures, 2 were surplus to requirement, 6 were reserve subjects. Subjects randomized were 18.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RB Naproxen (Test) First, Then Aleve Naproxen (Reference)</title>
          <description>Participants first received RB naproxen sodium 2 x 220 mg tablets single-oral dose in a fasting condition. After a washout period of 5-8 Days, they then received Aleve naproxen sodium 2 x 220 mg tablets single-oral dose in a fasting condition.</description>
        </group>
        <group group_id="P2">
          <title>Aleve Naproxen (Reference) First, Then RB Naproxen (Test)</title>
          <description>Participants first received Aleve naproxen sodium 2 x 220 mg tablets single-oral dose in a fasting condition. After a washout period of 5-8 Days, they then received RB naproxen sodium 2 x 220 mg tablets single-oral dose in a fasting condition.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout: 5-8 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>RB Naproxen Sodium 2 x 220 mg single dose by mouth under fasted condition.
Aleve® Naproxen Sodium 2 x 220 mg single dose by mouth under fasted condition.
There was a 5 to 8 days washout period between each administration.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.6" spread="9.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172" spread="11.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.69" spread="14.676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.025" spread="2.7857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under Plasma Concentration-time at Time t (AUC0-t)</title>
        <description>AUC0-t defines Area under the plasma concentration-time curve (AUC) from administration to the last quantifiable concentration at time t.</description>
        <time_frame>Pre-dose and at 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 15 mins, 1 hour 30 mins, 1 hour 45 mins, 2 hours, 2 hours 30 mins, 3, 4, 6, 9, 15 (Day 1), 24, 36 (Day 2), 48 (Day 3) and 72 (Day 4) hours post-dose</time_frame>
        <population>Pharmacokinetic (PK) Parameter Summary Set Population includes all subjects from the PK dataset with evaluable PK parameters for each treatment period.</population>
        <group_list>
          <group group_id="O1">
            <title>Test: RB Naproxen Sodium 2 x 220 mg</title>
            <description>RB naproxen sodium 2 x 220 mg tablets single dose by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Reference: Aleve Naproxen Sodium 2x220 mg</title>
            <description>Aleve naproxen sodium 2 x 220 mg tablets single dose by mouth under fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Plasma Concentration-time at Time t (AUC0-t)</title>
          <description>AUC0-t defines Area under the plasma concentration-time curve (AUC) from administration to the last quantifiable concentration at time t.</description>
          <population>Pharmacokinetic (PK) Parameter Summary Set Population includes all subjects from the PK dataset with evaluable PK parameters for each treatment period.</population>
          <units>h*μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="915" spread="207"/>
                    <measurement group_id="O2" value="909" spread="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax)</title>
        <time_frame>Pre-dose and at 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 15 mins, 1 hour 30 mins, 1 hour 45 mins, 2 hours, 2 hours 30 mins, 3, 4, 6, 9, 15 (Day 1), 24, 36 (Day 2), 48 (Day 3) and 72 (Day 4) hours post-dose</time_frame>
        <population>PK Parameter Summary Set Population</population>
        <group_list>
          <group group_id="O1">
            <title>Test: RB Naproxen Sodium 2 x 220 mg</title>
            <description>RB naproxen sodium 2 x 220 mg tablets single dose by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Reference: Aleve Naproxen Sodium 2x220 mg</title>
            <description>Aleve naproxen sodium 2 x 220 mg tablets single dose by mouth under fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax)</title>
          <population>PK Parameter Summary Set Population</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.9" spread="11.9"/>
                    <measurement group_id="O2" value="65.2" spread="9.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Rate Constant (Kel)</title>
        <description>Elimination Rate Constant (Kel) was calculated as the absolute value of the log-linear regression slope of the elimination phase (logged) over time (linear) using the post Cmax concentrations [at least 3 non-below the limit of quantification (BLQ)] that maximised the adjusted R2.</description>
        <time_frame>Pre-dose and at 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 15 mins, 1 hour 30 mins, 1 hour 45 mins, 2 hours, 2 hours 30 mins, 3, 4, 6, 9, 15 (Day 1), 24, 36 (Day 2), 48 (Day 3) and 72 (Day 4) hours post-dose</time_frame>
        <population>PK Parameter Summary Set Population</population>
        <group_list>
          <group group_id="O1">
            <title>Test: RB Naproxen Sodium 2 x 220 mg</title>
            <description>RB naproxen sodium 2 x 220 mg tablets single dose by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Reference: Aleve Naproxen Sodium 2x220 mg</title>
            <description>Aleve naproxen sodium 2 x 220 mg tablets single dose by mouth under fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination Rate Constant (Kel)</title>
          <description>Elimination Rate Constant (Kel) was calculated as the absolute value of the log-linear regression slope of the elimination phase (logged) over time (linear) using the post Cmax concentrations [at least 3 non-below the limit of quantification (BLQ)] that maximised the adjusted R2.</description>
          <population>PK Parameter Summary Set Population</population>
          <units>1/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0413" spread="0.00858"/>
                    <measurement group_id="O2" value="0.0414" spread="0.00673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration Curve From Administration to Infinity (AUC0-inf)</title>
        <description>Area under the plasma concentration curve from administration to infinity (AUC0-inf) was calculated as AUC0-t + (Ct/Kel) where Ct was the last quantifiable concentration at time t</description>
        <time_frame>Pre-dose and at 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 15 mins, 1 hour 30 mins, 1 hour 45 mins, 2 hours, 2 hours 30 mins, 3, 4, 6, 9, 15 (Day 1), 24, 36 (Day 2), 48 (Day 3) and 72 (Day 4) hours post-dose</time_frame>
        <population>PK Parameter Summary Set Population</population>
        <group_list>
          <group group_id="O1">
            <title>Test: RB Naproxen Sodium 2 x 220 mg</title>
            <description>RB naproxen sodium 2 x 220 mg tablets single dose by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Reference: Aleve Naproxen Sodium 2x220 mg</title>
            <description>Aleve naproxen sodium 2 x 220 mg tablets single dose by mouth under fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Curve From Administration to Infinity (AUC0-inf)</title>
          <description>Area under the plasma concentration curve from administration to infinity (AUC0-inf) was calculated as AUC0-t + (Ct/Kel) where Ct was the last quantifiable concentration at time t</description>
          <population>PK Parameter Summary Set Population</population>
          <units>h*μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="972" spread="232"/>
                    <measurement group_id="O2" value="963" spread="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Residual Area (AUC%Extrap)</title>
        <description>AUC%extrap represents the percentage of the AUC0-inf obtained by extrapolation, calculated as (1 - [AUC0-last/AUC0-inf]) multiplied by 100.</description>
        <time_frame>Pre-dose and at 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 15 mins, 1 hour 30 mins, 1 hour 45 mins, 2 hours, 2 hours 30 mins, 3, 4, 6, 9, 15 (Day 1), 24, 36 (Day 2), 48 (Day 3) and 72 (Day 4) hours post-dose</time_frame>
        <population>PK Parameter Summary Set population</population>
        <group_list>
          <group group_id="O1">
            <title>Test: RB Naproxen Sodium 2 x 220 mg</title>
            <description>RB naproxen sodium 2 x 220 mg tablets single dose by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Reference: Aleve Naproxen Sodium 2x220 mg</title>
            <description>Aleve naproxen sodium 2 x 220 mg tablets single dose by mouth under fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Residual Area (AUC%Extrap)</title>
          <description>AUC%extrap represents the percentage of the AUC0-inf obtained by extrapolation, calculated as (1 - [AUC0-last/AUC0-inf]) multiplied by 100.</description>
          <population>PK Parameter Summary Set population</population>
          <units>Percentage of AUC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.68" spread="2.03"/>
                    <measurement group_id="O2" value="5.58" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Until Cmax is First Achieved (Tmax)</title>
        <time_frame>Pre-dose and at 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 15 mins, 1 hour 30 mins, 1 hour 45 mins, 2 hours, 2 hours 30 mins, 3, 4, 6, 9, 15 (Day 1), 24, 36 (Day 2), 48 (Day 3) and 72 (Day 4) hours post-dose</time_frame>
        <population>PK Parameter Summary Set population</population>
        <group_list>
          <group group_id="O1">
            <title>Test: RB Naproxen Sodium 2 x 220 mg</title>
            <description>RB naproxen sodium 2 x 220 mg tablets single dose by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Reference: Aleve Naproxen Sodium 2x220 mg</title>
            <description>Aleve naproxen sodium 2 x 220 mg tablets single dose by mouth under fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Until Cmax is First Achieved (Tmax)</title>
          <population>PK Parameter Summary Set population</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" spread="1.35"/>
                    <measurement group_id="O2" value="1.31" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration (Elimination) Half-life (T1/2)</title>
        <time_frame>Pre-dose and at 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 15 mins, 1 hour 30 mins, 1 hour 45 mins, 2 hours, 2 hours 30 mins, 3, 4, 6, 9, 15 (Day 1), 24, 36 (Day 2), 48 (Day 3) and 72 (Day 4) hours post-dose</time_frame>
        <population>PK Parameter Summary Set population</population>
        <group_list>
          <group group_id="O1">
            <title>Test: RB Naproxen Sodium 2 x 220 mg</title>
            <description>RB naproxen sodium 2 x 220 mg tablets single dose by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Reference: Aleve Naproxen Sodium 2x220 mg</title>
            <description>Aleve naproxen sodium 2 x 220 mg tablets single dose by mouth under fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration (Elimination) Half-life (T1/2)</title>
          <population>PK Parameter Summary Set population</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3" spread="2.92"/>
                    <measurement group_id="O2" value="17.1" spread="2.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration at Each Planned Nominal Time-point (Cn)</title>
        <time_frame>Pre-dose and at 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 15 mins, 1 hour 30 mins, 1 hour 45 mins, 2 hours, 2 hours 30 mins, 3, 4, 6, 9, 15 (Day 1), 24, 36 (Day 2), 48 (Day 3) and 72 (Day 4) hours post-dose</time_frame>
        <population>PK Parameter Summary Set population</population>
        <group_list>
          <group group_id="O1">
            <title>Test: RB Naproxen Sodium 2 x 220 mg</title>
            <description>RB naproxen sodium 2 x 220 mg tablets single dose by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Reference: Aleve Naproxen Sodium 2x220 mg</title>
            <description>Aleve naproxen sodium 2 x 220 mg tablets single dose by mouth under fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration at Each Planned Nominal Time-point (Cn)</title>
          <population>PK Parameter Summary Set population</population>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" spread="14.8"/>
                    <measurement group_id="O2" value="16.1" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49" spread="22.7"/>
                    <measurement group_id="O2" value="47.3" spread="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.4" spread="20"/>
                    <measurement group_id="O2" value="54.1" spread="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" spread="13.1"/>
                    <measurement group_id="O2" value="53.6" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 15 mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6" spread="10.4"/>
                    <measurement group_id="O2" value="52.9" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 30 mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.9" spread="10.1"/>
                    <measurement group_id="O2" value="52.5" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hr 45 mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5" spread="8.54"/>
                    <measurement group_id="O2" value="54" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.4" spread="8.05"/>
                    <measurement group_id="O2" value="53.4" spread="9.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hrs 30 mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3" spread="7.17"/>
                    <measurement group_id="O2" value="50" spread="8.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" spread="6.34"/>
                    <measurement group_id="O2" value="47.1" spread="7.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.8" spread="6"/>
                    <measurement group_id="O2" value="41.8" spread="6.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1" spread="6.34"/>
                    <measurement group_id="O2" value="34.6" spread="6.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.34" spread="5.21"/>
                    <measurement group_id="O2" value="27.7" spread="5.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.42" spread="23.5"/>
                    <measurement group_id="O2" value="18.9" spread="3.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.61" spread="26.1"/>
                    <measurement group_id="O2" value="13.3" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="35"/>
                    <measurement group_id="O2" value="7.9" spread="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" spread="39"/>
                    <measurement group_id="O2" value="4.98" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>72 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.938" spread="42.3"/>
                    <measurement group_id="O2" value="2.15" spread="0.764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Adverse Events (AEs)</title>
        <description>Intensity was determined by the Investigator
Mild = AE does not limit usual activities; subject may experience slight discomfort.
Moderate = AE results in some limitation of usual activities; subject may experience significant discomfort.
Severe = AE results in an inability to carry out usual activities; subject may experience intolerable discomfort or pain.
Relationship to Investigational Medicinal Products (IMP)
Certain = AE was definitely caused by IMP. Probable = Most likely that the AE was caused by IMP. Possible = Reasonable suspicion that the AE was caused by IMP Unlikely = Slight, but remote, chance that the AE was caused by IMP but the balance of judgment is that it was most likely not due to the IMP.
Unrelated = No possibility that the AE was caused by IMP Un-assessable/Unclassified = Insufficient information to be able to make an assessment.
Conditional/Unclassified = Insufficient information to make an assessment at present.</description>
        <time_frame>Up to follow-up day 7</time_frame>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Test: RB Naproxen Sodium 2 x 220 mg</title>
            <description>RB naproxen sodium 2 x 220 mg tablets single dose by mouth under fasted condition</description>
          </group>
          <group group_id="O2">
            <title>Reference: Aleve® Naproxen Sodium 2 x 220 mg</title>
            <description>Aleve naproxen sodium 2 x 220 mg tablets single dose by mouth under fasted condition.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Adverse Events (AEs)</title>
          <description>Intensity was determined by the Investigator
Mild = AE does not limit usual activities; subject may experience slight discomfort.
Moderate = AE results in some limitation of usual activities; subject may experience significant discomfort.
Severe = AE results in an inability to carry out usual activities; subject may experience intolerable discomfort or pain.
Relationship to Investigational Medicinal Products (IMP)
Certain = AE was definitely caused by IMP. Probable = Most likely that the AE was caused by IMP. Possible = Reasonable suspicion that the AE was caused by IMP Unlikely = Slight, but remote, chance that the AE was caused by IMP but the balance of judgment is that it was most likely not due to the IMP.
Unrelated = No possibility that the AE was caused by IMP Un-assessable/Unclassified = Insufficient information to be able to make an assessment.
Conditional/Unclassified = Insufficient information to make an assessment at present.</description>
          <population>Safety population</population>
          <units>Number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Emergent Adverse Event (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE Leading to Withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE of mild intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE of moderate intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE of severe intensity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Certain related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possible related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unlikely related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unrelated related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Conditional/Unclassified related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unassessable/Unclassifiable related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to follow-up day 7</time_frame>
      <desc>Treatment-emergent adverse events (TEAEs), i.e., existing conditions that worsened or events that occurred during the course of the study after first administration of IMP and before the end of the study, are included.</desc>
      <group_list>
        <group group_id="E1">
          <title>Test: RB Naproxen Sodium 2 x 220 mg</title>
          <description>RB Naproxen Sodium 2 x 220 mg single dose by mouth under fasted condition.</description>
        </group>
        <group group_id="E2">
          <title>Reference: Aleve® Naproxen Sodium 2 x 220 mg</title>
          <description>Aleve Naproxen Sodium 2 x 220 mg single dose by mouth under fasted condition.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Director, Clinical Research</name_or_title>
      <organization>Reckitt Benckiser Healthcare (UK) Ltd</organization>
      <phone>+44 (0) 1482326151</phone>
      <email>clinicalrequests@rb.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

